District Court Denies Takeda's Motion for a New Trial

Shelby Riney, of the firm's Commercial Litigation department, authored, "District Court Denies Takeda's Motion for a New Trial," for the ABA Section of Litigation, Products Liability, News & Developments. The U.S. District Court for the Western District of Louisiana denied the Rule 59 Motion for a new trial filed by Takeda Pharmaceuticals U.S.A. and related entities (Takeda) in a case involving Takeda's anti-diabetes medication Actos and allegations that it causes bladder cancer (Actos Product Liability Litigation). Among other issues, Takeda contended that the jury's $9 billion punitive award resulted from passion and prejudice. While the court remitted the jury's $9 billion punitive award to $37 million, it defended its finding that Takeda acted in bad faith when it spoliated evidence.

To read the full article, click here.

Share Page On LinkedIn

Related Attorneys

Shelby K. Riney



(215) 665-5521

Related Practices